Positron Emission Tomography of Amyloid in Alzheimer's Disease
Alzheimer's Disease
About this trial
This is an interventional diagnostic trial for Alzheimer's Disease focused on measuring Alzheimer's disease, amyloid, PET, PIB, FDDNP
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of probable Alzheimer's disease (NINCDS-ADRDA criteria) Clinical diagnosis of MCI according to the criteria of Petersen Age between 60 and 80 years Written informed consent of each subject. Hb must be >8 mmol \ litre at the time of the screening for males and >7 mmol\litre for females. Weight >50 kg All subjects have to be "wilsbekwaam" Exclusion Criteria: Any clinical significant abnormality of any clinical laboratory test Any subject who has received any investigational medication within 30 days prior to the start of this study, or who is scheduled to receive an investigational drug. Major psychiatric or neurological disorder other than AD History of AD in first degree relatives (controls only) History of alcohol and/or drug abuse (DSM-IV criteria) Any sign of cardiovascular disease including ECG Claustrophobia Mini Mental State Score below 20 Use of non-steroid anti-inflammatory drugs Abnormalities on MRI other than white matter changes or an incidental small lacunar lesion. Blood donation within 3 months before the scan day Metal objects in or around the body (braces, pacemaker, metal fragments) Use of antithrombotics and ASA Fall ≤ 6 months or any relevant gait disorder Need for elective surgery ≤ 3 months
Sites / Locations
- VU University Medical Center